Recently, Chongqing Federation of Industry and Commerce released the "Top 100 list of Chongqing Private Enterprises' Science and Technology Innovation Index", and Zybio ranked 3rd on the list. At the same time, Zybio ranked 8th on the "Top 50 Chongqing Private Enterprises' R&D Investment 2022".

As a high-tech enterprise, Zybio insists on the strategy of innovation-driven development, focuses deeply on the frontier technology of in vitro diagnosis, and takes R&D as the core driving force to promote the sustainable development of the enterprise. Attaching importance to talent development, the number of R&D personnel exceeds one-third of the total number of employees, also the team of doctors formed to focus deeply on the frontier of science and technology, and the company's R&D investment ratio has always been in the leading position in the industry. As a post-doctoral research station, Zybio has obtained more than 70 invention patents and 447 product registrations. In 2022, it has been awarded the medal by the State Intellectual Property Office and the World Intellectual Property Organization for the invention patent of "Matrix-assisted laser-resolved spectrometer sample target device”. The 23rd China Patent Award was jointly selected by the State Intellectual Property Office and the World Intellectual Property Organization.

Zybio has set up eight R&D centers in Chongqing, Beijing, Shanghai, Guangzhou, Shenzhen, Nanjing, Xiamen and Changchun, and its main business covers biochemical, immunological, molecular, POCT, clinical tests, microbiology, pathology, urinalysis and other diagnostic products as well as upstream raw materials. The company has made a comprehensive layout in the core technology areas of biological raw materials and chemical raw materials, and has made achievements in core technologies such as genetically engineered antigens/antibodies, nanomaterials for diagnostics, development of high precision diagnostic instruments and core components, amplification of multiple labeling signals, and rapid nucleic acid extraction and detection.

Traceability is the only way to achieve standardization of test medical results. In line with its mission of "making diagnosis more accurate and life more healthy", Zybio has never stopped pursuing product quality while focusing on technological innovation. In order to ensure the reliability of the measurement results of IVD products, the company has established a standardized reference measurement laboratory, which is responsible for the traceability and quality evaluation of products. The key project has passed the International Reference Laboratory Proficiency Assessment (IFCC-RELA), the highest level of quality evaluation in the global clinical chemistry field. In 2022, the expansion of the reference measurement project was approved by the China National Accreditation Service for Conformity Assessment (CNAS) in 2022 International Medical Reference Laboratory Proficiency Assessment (RELA2022) results were announced, all the projects in which Zybio participated met the requirements.

About Zybio

Zybio Inc. is a high-tech enterprise specialized in R&D, manufacture, sales and technical services of in vitro diagnostic reagents and equipment, with the headquarter and manufacturing center located in Dadukou District, Chongqing.

Zybio has more than 3,300 employees worldwide, of which R&D personnel account for more than 30% . Nearly 50% of R&D personnel have master's degree or above. The company compared to spend no less than 15% of sales revenue on its research and development.

As a postdoctoral programme, Zybio is dedicated to attract more talents to focus on the cutting-edge technology in IVD field and take product research and development as the core driving force in the future’s continuous and rapid development. We have established several R&D centers distributed in China, like Chongqing R&D center, Beijing R&D center, Guangzhou R&D center, Shenzhen R&D center, Nanjing R&D center Xiamen R&D center and Changchun R&D center . The company’s main product covers clinical chemistry, immunoassay, molecular diagnosis, POCT, hematology, microbiology, pathological and other diagnostic products. It also has a comprehensive layout in core technical fields such as biological raw materials and chemical raw materials. The company has developed a wide range of core technologies such as genetic engineering antigens/antibodies, diagnostic nanomaterials, high-precision diagnostic equipment and core component, multiple label signal amplification, and rapid nucleic acid extraction and detection.

Zybio has 100,000 m2 manufacture plant, equipped with a modern qualified production workshop, and has 19 production lines including reagents and equipment. We have setup an international standard quality system and our products have passed ISO 90001 and ISO 13485. All products have passed strict quality inspection before shipping. The current production capacity can reach 3.0 billion kits of reagent and 35,000 equipment per year.